These findings suggest that the observed anti-leukemic activity in TP53 mutated MDS/AML and particularly erythroid leukemias is likely associated with higher expression of the target and not cell-intrinsic sensitivity to the ADC. Here, TP53 is linked to acute myeloid leukemia.